---
title: "Weekly Recap | OSR Health -12.34%, hit with Nasdaq delisting notice"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296669859.md"
description: "OSR Health fell 12.34% this week to close at $0.277, underperforming the S&P 500’s 1.43% decline by roughly 10.91 percentage points. The session was extremely volatile, with an intraweek amplitude of 164.47%. Monday (17 August) saw the stock surge to an intraday high of $0.80 before a steady retreat. By midweek and into Friday, the price tested the weekly low of $0.2693, with volume surging far above its median levels."
datetime: "2026-08-22T05:27:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296669859.md)
  - [en](https://longbridge.com/en/news/296669859.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296669859.md)
generator: "portal-rs"
---

# Weekly Recap | OSR Health -12.34%, hit with Nasdaq delisting notice

## The Week

OSR Health fell 12.34% this week to close at $0.277, underperforming the S&P 500’s 1.43% decline by roughly 10.91 percentage points. The session was extremely volatile, with an intraweek amplitude of 164.47%. Monday (17 August) saw the stock surge to an intraday high of $0.80 before a steady retreat. By midweek and into Friday, the price tested the weekly low of $0.2693, with volume surging far above its median levels.

## Key Events

The week’s narrative centred on Nasdaq compliance troubles. Early in the session, the stock rallied sharply intraday amid mentions of a shareholder loyalty programme and an improved medical loss ratio, but the tone quickly soured. The company flagged unusual Nasdaq trading activity, noting the stock was nearing the $1 minimum bid requirement. OSR Health then formally received a delisting determination from Nasdaq’s staff and announced its intent to appeal before a Hearings Panel. By week’s end, the firm released a statement saying it was preparing its appeal while advancing business catalysts and continuing its mission.

## Analyst Ratings

A single analyst covers OSR Health, rating it a buy. The consensus recommendation is a strong buy, with a consensus target price of $10, implying an upside of roughly 3,510% from the current price. Both the high and low target estimates sit at $10, reflecting a unified view from the sole covering broker. Within the biotech industry, the stock’s rating rank is 460 out of 505 companies.

## The Week Ahead

On the macro calendar, the US will release a batch of housing and consumer data on Tuesday, 25 August, including the FHFA House Price Index, the Case-Shiller 20-City Index, new home sales, and the Consumer Confidence Index. For OSR Health, the market’s attention will remain fixed on the delisting appeal. Any update on the hearing schedule or a roadmap to regain compliance could serve as a key catalyst for the stock.

## In Short

OSR Health’s week swung from a sharp intraday spike to a deep sell-off after receiving a Nasdaq delisting notice, underscoring acute market anxiety about its listing status. The tension lies between the company’s stated commitment to appeal and advance its business catalysts—backed by a single broker’s strong buy rating and a target price far above spot—and the stark reality of a compliance crisis and violent price swings. The path forward hinges on the firm’s ability to present a credible remediation plan at the upcoming hearing.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [OSRH.US](https://longbridge.com/en/quote/OSRH.US.md)

## Related News & Research

- [OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission  | OSRH Stock News](https://longbridge.com/en/news/296636382.md)
- [OSR Health CEO says two subsidiaries draw out-licensing interest as Nasdaq bid deadline nears](https://longbridge.com/en/news/295540141.md)
- [Devoted Health is raising a new round of funding at a $25 billion valuation](https://longbridge.com/en/news/296648147.md)
- [Endovia Health Sciences to Begin Trading as EDVA on NYSE American Aug 24](https://longbridge.com/en/news/296620824.md)
- [Insider Selling: Sotera Health (NASDAQ:SHC) Chairman Sells 850,000 Shares](https://longbridge.com/en/news/296401553.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**